F8 and hemophilia A: Long-term follow-up assesses durability, safety, and immune-related challenges following gene therapy.<h4>Aim</h4>Evaluation of six years of post-infusion outcomes of a patient receiving valoctocogene roxaparvovec, focusing on FVIII expression, immune response management, and adverse events (AEs).<h4>Methods</h4>A 44-year-old male with severe hemophilia A received a single infusion of valoctocogene roxaparvovec (6 × 10<sup>13</sup> vector genomes/kg) in the GENEr8-1 study.